Evotec (NASDAQ:EVO) Reaches New 1-Year Low – What’s Next?

Evotec AG (NASDAQ:EVO – Get Free Report) hit a new 52-week low on Friday. The stock traded as low as $1.32 and last traded at $1.32, with a volume of 77,088 shares. The stock had previously closed at $1.45.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on EVO shares. HC Wainwright lifted their price objective on shares of Evotec from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.50.

Read Our Latest Stock Report on EVO

Evotec Trading Down 9.0%

The stock has a 50 day moving average of $1.56 and a two-hundred day moving average of $2.37. The company has a quick ratio of 2.19, a current ratio of 2.32 and a debt-to-equity ratio of 0.65.

Institutional Investors Weigh In On Evotec

A hedge fund recently raised its position in Evotec stock. Optiver Holding B.V. lifted its stake in shares of Evotec AG (NASDAQ:EVO – Free Report) by 598.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 283,576 shares of the company’s stock after purchasing an additional 242,973 shares during the quarter. Optiver Holding B.V. owned about 0.08% of Evotec worth $709,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

(Get Free Report)

Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Its work spans early-stage research through preclinical and clinical development, using expertise in areas such as biology, chemistry and data-driven drug discovery. The company supports programs across multiple therapeutic areas and develops both small-molecule and biologic medicines. Its Just-Evotec Biologics business focuses on the development and production of biologics, including services intended to help partners advance treatments from research toward clinical and commercial use.

Featured Stories

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.